EW - EW エドワ―ズライフサイエンス （）

Edwards Lifesciences (NYSE: EW ) has outperformed the market over the past 10 years by 11.87% on an annualized basis producing an average annual return of 22.12%. Currently, Edwards Lifesciences has a market capitalization of $50.90 billion. Buying $1000 In EW: If … Full story available on Benzinga.com

Illumina''s (ILMN) board has elected Hologic (HOLX) CEO Stephen MacMillan as its new non-executive chair and Edwards Lifesciences (EW) CFO Scott Ullem as an independent director.

WILMINGTON, DE / ACCESSWIRE / June 1, 2023 / Transparency Market Research Inc. - The Global Hemodynamic Monitoring Market was valued at US$ 1.2 Bn in 2021 and is projected to surpass US$ 2.2 Bn by 2031, expanding at a CAGR of 5.8% between 2022 and 2031. Increase in the elderly population, rise in prevalence of chronic illnesses, and surge in demand for upgraded monitoring systems are projected to boost the global hemodynamic monitoring systems market. Additionally, increase in healthcare spending and rise in awareness about the benefits of hemodynamic monitoring are anticipated to fuel market demand. The global industry is projected to benefit significantly from technical breakthroughs in hemodynamic monitoring equipment. Development of wireless, non-intrusive monitoring systems, and integration of AI and ML technologies, is the major focus of manufacturers. Remote monitoring as well as telemedicine have gained popularity due to the COVID-19 pandemic, which is expected to fuel the expansion of the hemodynamic monitoring system market in the near future.

Edwards Lifesciences (NYSE: EW ) has outperformed the market over the past 10 years by 13.2% on an annualized basis producing an average annual return of 22.67%. Currently, Edwards Lifesciences has a market capitalization of $50.82 billion. Buying $100 In EW: If … Full story available on Benzinga.com

The share price of Edwards Lifesciences Corporation (NYSE:EW) fell to $83.83 per share on Thursday from $84.24. While Edwards Lifesciences Corporation has underperformed by -0.49%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EW fell by -26.15%, with highs and lows ranging from $131.73 to $81.87, […]

Edwards Lifesciences Corporatio found using ticker (EW) now have 18 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 130 and 97 with a mean TP of 116.11. Given that the stocks previous close was at 83.59 this would indicate that there is a potential upside of 38.9%. The day 50 moving average is 96.99 while the 200 day moving average is 105.96. The market capitalisation for the company is $51,065m. Company Website: https://www.edwards.com [stock_market_widget type="chart" template="basic" color="green" assets="EW" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $70,931m based on the market concensus. Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Currently, Edwards Lifesciences Corporation’s (EW) stock is trading at $84.44, marking a fall of -0.92% from last night’s close. At this price, the stock is -35.90% below its 52-week high of $131.73 and -0.87% above its 52-week low of $85.18. Based on the past 30-day period, the stock price is -14.38% below the high and […]

Edwards Lifesciences Corporatio found using ticker (EW) have now 18 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 130 and 97 and has a mean target at 116.39. Given that the stocks previous close was at 88.83 this is indicating there is a potential upside of 31.0%. There is a 50 day moving average of 98.01 and the 200 moving average now moves to 106.55. The market capitalisation for the company is $54,053m. You can visit the company''s website by visiting: https://www.edwards.com [stock_market_widget type="chart" template="basic" color="green" assets="EW" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $70,823m based on the market concensus. Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Tuesday''s top analyst upgrades and downgrades included Adobe, Cheniere Energy, CNX Resources, Edwards Lifesciences, EOG Resources, Huntsman, Kraft Heinz, NCR, Peloton Interactive, PulteGroup, Take-Two Interactive Software and UDR.

Related Stocks: EW , AMZN , EFX , VNT , HON , TSLA , KD ,

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.

Following a decline of more than 15% in January, Edwards Lifesciences (EW) has bounced back after UBS upgraded the cardiac equipment company to Buy from Neutral, citing its potential in

Las Vegas, USA, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Vascular Access Devices Market is Expected to Surge at a Significant CAGR of 6.64% and is also Contemplated to Reach Upto USD 6.13 Billion by 2026, Estimates DelveInsight The Vascular Access Device market is anticipated to grow tremendously in the coming years due to many factors which include the rising prevalence of end-stage renal diseases and the rising number of vascular access surgeries, these are striving the Vascular Access Devices demand, thus driving the growth of Vascular Access Device market. DelveInsight''s Vascular Access Devices Market Insights and Forecast report provides the current and forecast Vascular Access Devices, upcoming innovation in the devices, individual market shares of the devices, challenges, drivers and barriers, market trends, and key competitors in the Vascular Access Devices. Some of the essential takeaways from the Vascular Access Devices Market report: According to DelveInsight analysis, North America is expected to dominate the overall Vascular Access Devices Market during the forecast period.